compound tough comp
highlight strong quarter
think highlight within thermo fisher strong organ growth
compani abl capit healthi end market condit
custom valu proposit drive share gain market particular
believ thermo fisher abil deliv growth capital-heavi
analyt instrument segment comp help assuag concern
around compani abil compound growth head look
across thermo fisher busi end market past year noth stand
us one-tim natur end market perspect notabl
thermo fisher post high-teen growth biopharma repres acceler
recent trend end market remain strong end market tracker
suggest current visibl good earli geograph standpoint
thermo fisher leverag scale china anoth quarter growth note
share gain order growth stronger revenu growth impli
sale period
final look product famili highlight thermo fisher deliv
strong growth across import franchis specif call
analyt instrument busi sale biopharma servic
sale bioproduct sale bioscienc sale addit
strength research safeti market channel help drive organ growth
rate lab product servic segment organ growth specialti dx
thermo fisher channel choic custom overal stack
result versu peer think undeni thermo fisher take
advantag favor end market condit grow market share across
number busi result increas convict thesi
overweight rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target driven
continu biopharma strength well futur
capit deploy upsid case reflect
upsid ep
thermo fisher exposur econom activ
end market could impact growth
specif industri end market repres
around revenu downsid case
reflect downsid ep
think highlight within thermo fisher strong organ growth
compani abl capit healthi end market condit
custom valu proposit drive share gain market particular believ
thermo fisher abil deliv growth capital-heavi analyt
instrument segment comp help assuag concern around
compani abil compound growth head look across thermo
fisher busi end market past year noth stand us
one-tim natur end market perspect notabl thermo fisher post high-
teen growth biopharma repres acceler recent trend end
market remain strong end market tracker suggest current visibl good
earli geograph standpoint thermo fisher leverag scale china
anoth quarter growth note share gain order growth
stronger revenu growth impli sale period
final look product famili highlight thermo fisher deliv strong
growth across import franchis specif call
analyt instrument busi sale biopharma servic sale
bioproduct sale bioscienc sale addit strength
research safeti market channel help drive organ growth rate lab
product servic segment organ growth specialti dx thermo
fisher channel choic custom overal stack result versu peer
think undeni thermo fisher take advantag favor end market
condit grow market share across number busi result
increas convict thesi overweight rate
better quarterli result thermo fisher rais guidanc account
strong oper perform off-set less favor fx believ continu
conserv shown chart compani forecast revenu
billion midpoint billion previous
repres total revenu growth vs previous
includ roughli acquir month patheon note today spot rate
fx remain headwind roughli posit organ growth rate
guidanc call roughli midpoint previou guidanc
alway guidanc assum normal purchas trend account
impact potenti budget flush macro environ continu posit
believ rais outlook could still prove conserv
ep project rang y/i
midpoint versu previou rang rel prior guidanc
increas ep due tailwind organ trend benefit lower
interest expens tax headwind less favour fx
addit strateg invest keep mind thermo fisher guidanc
includ capit deploy beyond alreadi announc activ includ share
repurchas dividend oper margin expect increas
core improv off-set acquisit
addit thermo fisher anticip tax rate
share outstand interest expens midpoint
expect focu confer call relat thermo fisher
bioproduct busi appear post healthi growth
quarter manag optimist long-term driver bioproduct
market believ
custom valu proposit posit compani well
specif confer call ceo marc casper note anoth strong quarter
pharma busi perspect bioproduct strong
chromatographi mass spectrometri research channel pharma servic
busi includ clinic trial legaci patheon good quarter
omit good quarter saw excel
momentum across portfolio way think end market
scalabl relationship custom whether smaller compani larger one
commerci serv differ way great access decision-
maker scale relationship everi time bring new
capabl allow us yet anoth dialogu across whole portfolio
add organ inorgan driven great momentum busi
addit appear healthi trend bioproduct continu
fourth consecut quarter manag tout compani
outperform peer report earn thu far note
danah pall biotech post mid-teen growth previou upper bar
result bioproduct
among life scienc tool peer believ thermo fisher uniqu capabl serv
biopharma end market under-appreci serv long-term
differenti growth driver compani altogeth biopharma end market
repres around thermo fisher revenu grown least m-hsd
compani foundat start research capabl channel busi
consolid histor driven growth thermo fisher aggreg client
wallet thermo fisher capabl product qa/qc continu perform well
global access therapeut drive demand liquid chromatographi beyond
thermo fisher uniqu capabl repres around revenu includ
bioproduct contract drug manufactur patheon clinic trial logist
see sustain long-term growth driver hsd-low-teen segment
believ long-term structur tailwind support visibl import growth
driver thermo fisher
thermo fisher uniqu biopharma exposur repres revenu mm
thermo fisher continu activ capit deploy believ
compani continu flexibl pursu larger start thermo
fisher acquir integenx march tuck-in deal area rapid forens
quarter compani announc acquisit gatan expect close year-
end advanc bioprocess asset cover
barclay analyst kristen stewart thermo fisher return million sharehold
dividend million share repurchas compani
activ highlight acquisit patheon close lead global
provid high-qual drug develop deliveri solut biopharma market
addit patheon acquisit thermo fisher activ share
repurchas complet number tuck-in acquisit includ finess solut
informat reflect compani complet acquisit
affymetrix march fei co acquisit septemb
largest transact compani histori thermo fisher complet billion
capit deploy call ceo casper note thermo fisher
substanti flexibl addit attract opportun present
term free cash flow project thermo fisher gener billion
estim thermo fisher end quarter net debt ttm ebitda
ttm result thru total trial total total biopharma total fisher biopharma contribut organ growthrevscdmo -patheonorgan growthrevsclin trial logisticsorgan growthrevsbioproductionorgan growth barclay thermo fisher scientif inc
net debt ttm ftm ebitda
septemb thermo fisher announc million acquisit
bioprocess asset busi provid technic servic
pepton enhanc cell cultur media natur fit thermo fisher upstream
bioproduct offer cell cultur media single-us technolog asset
gener around million revenu estim around million
ebitda assum asset gener similar margin thermo fisher
bioproduct busi today modestli lss averag
transact expect close earli
june thermo fisher announc million acquisit gatan
subsidiari roper cover barclay analyst julian mitchel view
acquisit quintessenti tuck-in deal thermo fisher allow
compani streamlin fei oper manufactur develop
electron microscop modestli accret compani gatan
manufactur instrument softwar primarili use input
process develop electron microscop thermo fisher fei co market
leader electron microscopi major custom gatan
chanc catch thermo fisher announc appear
real opportun drive synergi across fei gatan given vertic integr
asset acquisit small revenu perspect
forecast believ earn contribut given
healthi margin thermo fisher uniqu posit gener integr
save thermo fisher appear natur home asset like abl
gener synergi hand competitor would abl achiev
deal aim provid cost advantag bring gatan technolog hous
though also see potenti advantag time innov driven better
coordin activ context synergi wouldnt
surpris thermo fisher pay multipl ebitda ultim level
depend synergi deal expect close end
fund cash view deal anoth great exampl highli strateg
acquisit thermo fisher compani continu lot
opportun ahead consolid industri
patheon clearli excit around acquisit believ
signific opportun take share win busi improv
debt ttm ebitdanet debt ntm ebitda barclay thermo fisher scientif inc
profit asset remind billion acquisit patheon close
end august part lab product servic divis
acquisit make thermo fisher one market leader
contract drug
manufactur own patheon thermo fisher believ remov element
complex suppli chain biopharma custom mani biopharma
sponsor thermo fisher largest supplier spend weve seen
cro industri industri pressur sponsor led consolid number
trust supplier choos work similarli small mid-siz biotech
compani dont capabl manufactur api drug
thermo fisher see natur cross-sel opportun compani clinic
trial logist busi given thermo fisher scale biopharma servic like
biopharma sponsor alreadi work compani clinic
trial logist patheon provid logic hand-ov clinic trial logist busi
drug manufactur thermo fisher provid pack ship servic
trial lot risk handoff clinic trial work
thermo fisher believ
industri consolid around time
addit custom also need cold chain servic thermo fisher provid
charg real value-ad servic custom thermo fisher
intend keep ad capit select franchis time continu
strategi patheon pursu stand-alon entiti
thermo fisher note patheon track ahead deal model term
integr deal accret remind thermo fisher guid investor
year accret million ebit cost revenu synergi
year term revenu synergi million year million
ebit thermo fisher note alreadi receiv inbound request cross-
sell clinic trial logist addit thermo fisher brand credibl
custom make natur partner outsourc work aggreg
share compani see pipelin small molecul biotech
choic outsourc thermo fisher count
signific amount chang outsourc penetr could repres
upsid term cost synergi million year beyond natur area
opportun public compani cost duplic administr area procur
better util manufactur footprint would provid lot earn
leverag thermo fisher see lot under-capac site own patheon
combin factor expect push margin mid-teen
compani averag time
call thermo fisher provid updat deal discuss
potenti custom ceo mark casper ad effect everi biotech
pharmaceut custom around world relationship thermo fisher
scientif today see multiproduct line servic line
relationship get larger larger relationship custom
work remiss servic line busi good
job creat valu therefor want work us close
scale compani depth offer abil
meaning relationship term impact custom
want spend time us creat new opportun
think receiv great momentum across custom base
fei co believ thermo fisher acquisit fei co fit well compani
 strategi re-emphas call fei co bring market lead
platform electron microscopi microscop compani believ em
platform complement portfolio mass spectrometri certain applic
specif highlight protein identif character thermo
fisher also highlight intend drive adopt fei technolog
biopharma market compani differenti product portfolio c-level
relationship help extend fei co reach thermo fisher impress fei
manufactur facil brno czech republ plan leverag site notabl
first month ownership thermo fisher note accret
compani forecast remind fei annual
count toward organ growth fei post double-digit growth
revenu billion came better estim billion
grew y/i driven mostli better organ growth higher
 fx consist forecast organ growth increas
y/i better forecast guidanc fx headwind
revenu growth acquisit ad revenu sell day
chang y/i result truli apples-to-appl note one addit sell
day though fall weekend
quarterli revenu mm total organ growth
store revenu growth segment
revenu contribut segment
non-gaap ep increas y/i came better
estim street compani tax rate
expect serv tailwind ep versu model
non-gaap ep growth
adjust oper incom million came forecast
million grew y/i oper margin declin y/i
came expect core margin increas off-set
headwind relat fx acquisit gross margin lower
expect wherea sg came lower expect
revenu like mix driven expens revenu
higher expect
adj oper incom mm growth
improv oper margin y/i
industri end market commentari solid importantli compani saw
continu strength biopharma end market high-teen growth y/i
confer call manag elabor trend experienc market
academ govern end market grew mid-singl digit quarter
benefit particular strength thermo fisher see flow
fund healthi nih budget healthcar clinic grew mid-singl digit
thermo fisher achiev high-teen growth biopharma repres
acceler recent trend strength broad-bas compani
highlight bioproduct chromatography/mass spectrometri pharma servic
research safeti end market channel compani benefit healthi market
environ well share gain due compani unmatch product breadth
notabl trend industri end market remain solid growth acceler
high-singl digit thermo fisher macro-sensit busi chemic
analysi strong quarter
manag commentari quarter
life scienc solut total organ growth
estim life scienc solut revenu came expect billion
increas y/i stronger organ growth drove revenu beat remind
follow hurrican inventori destock issu like thermo fisher
bioproduct busi benefit easier comp addit strong underli
growth trend quarter currenc roughli headwind growth
roughli line estim headwind segment oper incom
scienc growth particularli strong led growthexcel growthstrong growthmor mutedmodest growthstrong growthstrong growthveri growthgrowth leaderbiosciencesstrong demandparticularli strong growthstrong growthstrong growthstrong growthveri growthgrowth leadernext sequencingstrong growthteen growthl growthexcel growthstrong demandstrong growthveri growthgrowth leaderet analysi growthstrong demandveri growthanalyt appliedcontinu core weaknessindustri soft appli well lsd overallindustri continu weaknessgrew lsd appli strong order industrialgrew compani averag appli safeti channel industrialgrew compani averag appli return growth chemicalmsd growth good china growthmsd growthhsd growthmsd growthhsd growthmass spechsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthveri growthveri growthchromatographystrong growthhsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthveri growthveri growthfei companystrong oper executionexcel oper performancedouble-digit growthstrong growthstrong growthveri growthveri growthspecialti dx clinic dxsolid growth across segmentsimmuno-dx similar trend good growth immuno transplant dxsimilar trend lsd strength clinic similar trend lsd strength clinic transplant particularli stronglsd growth transplant immunodiagnosticslsd strong season busi clinic transplant dxlsd particularli strong healthcar channelmsd transplant clinic diagnost channelmsd channel transplant clinic diagnosticslab product govtlsd growthlsd growth grew slightli lsd growthlsd growthlsd growthmsd growth europ chinahsd growthmsd growthhsd growthmsd growthpharma biotechhsd growthldd growthhsd growthhsd growthmsd growthmsd growthmid-teen growthhigh-teen growthbiopharma servicesveri strong growth growth littl slower particularli strong strong perform unfavor mix biopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesgrow wellstrong growthstrong growthstrong growthldd growthlow-teensldd growthldd growthhsd growthldd growthlow-teensmid-teenslow-teenslow-teenschinahigh-teensmid-teenshigh-teensstrong growthjapannorth americamsd growthlsd growthlsd growthlsd growthlsd growthhsd growthlsd growthmsd growthhsd growtheuropemsd growthlsd growthlsd growthmsd growthmsd growthlsd growthmsd growthmsd growthmsd growthhsd growthhsd growthrowhsd declinemsd declinelsd declinelsd declineflatflatmsd growthlow-teensmsd growthlow-teenshsd growth barclay thermo fisher scientif inc
million quarter increas y/i adjust oper margin
y/i
analyt instrument total organ
instrument million stronger
expect revenu increas y/i organ currenc
headwind quarter roughli line estim headwind sequenti
organ growth improv growth view healthi
consid increasingli difficult comp
recent growth rate accret segment averag fei co like help organ
growth quarter acquisit includ integenx contribut acquir growth
quarter approxim segment oper incom increas y/i
million oper margin y/i
specialti diagnost organ organ growth
estim specialti diagnost result solid organ revenu
expect organ growth vs forecast currenc headwind
quarter roughli line estim headwind report revenu
improv adjust oper incom increas y/i million
oper margin y/i
laboratori product servic segment rev busi return
strength organ organ growth
estim laboratori product servic segment revenu came
expect quarter total revenu increas y/i organ revenu
increas acquisit patheon contribut segment revenu growth
line estim keep mind patheon transact annual end
august busi contribut one month organ growth quarter currenc
headwind line estim headwind adjust ebit
increas y/i million oper margin declin
geograph commentari strong highlight growth china
despit difficult comparison demand asia-pacif continu low-teen growth
highlight strength china thermo fisher remain encourag china
market despit rhetor around trade custom behavior region remain
encourag ceo casper note compani saw broad end market strength
region thermo fisher continu believ industri lead scale breadth
allow compani differenti region compani deliv high-
singl digit growth north america high-singl digit growth europ rest
world grew high-singl digit thermo fisher continu excit
opportun emerg market believ benefit scale
flow oper strong billion adjust net incom
capital-expenditure million repres revenu y/i thermo fisher
deploy million dividend sharehold manag repurchas
million share quarter come addit activ recent histori
august acquisit patheon recent announc acquisit
gatan bd bioproduct asset estim thermo fisher
end quarter net debt ttm ebitda give thermo fisher flexibl
pursu acquisit modest repurchas opportun present
cffo compon trend cffo free capital-expenditure mm
growthldd growthlow-teensldd growthldd growthhsd growthldd growthlow-teensmid-teenslow-teenslow-teenschinahigh-teensmid-teenshigh-teensstrong growthjapannorth americamsd growthlsd growthlsd growthlsd growthlsd growthhsd growthlsd growthmsd growthhsd growtheuropemsd growthlsd growthlsd growthmsd growthmsd growthlsd growthmsd growthmsd growthmsd growthhsd growthhsd growthrowhsd declinemsd declinelsd declinelsd declineflatflatmsd growthlow-teensmsd growthlow-teenshsd flowcffo net incom barclay thermo fisher scientif inc
thermo fisher mm except ep reportedincom growth profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay thermo fisher scientif inc
estestestestestestestestestincom statement growth growth growth organ adj product product product revenu inc servic servic gross margin inc sg stock comp total sg product margin oper incom margin improv w/ improv annual bs annual bs debt item expens pre-tax tax benefit net averag sharesbas ep continu opsbas adj adj full-year barclay thermo fisher scientif inc
thermo fisher statement flow
estestestestestestestesteststat activitiesnet discontinu dispos discontinu continu defer incom gain sale stock-bas interest expens convert benefit stock-bas comp charg sale non-cash expens work capitalaccount retir chang work cash provid continu cash use discontinu oper growth net activitiesacquisit net cash growth sale available-for-sal sale sale retir note increas restrict deriv invest activ use discontinu invest cash use invest activitiesnet proce issuanc long-term commerci paper convert long-term short-term note per proce issuanc proce issuanc employe benefit stock-compens financ activ cash provid financ rate effect equival equival growth adj net debt ttm barclay thermo fisher scientif inc
estestestestestestestestestbal sheet asset cash receiv less allow tax current current less accumul intang asset payrol employe incom accru current incom long-term convert debt sharehold liabil barclay thermo fisher scientif inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
